Faslodex Specific Clinical Experience Investigation

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

NCT03202862 ·Status: UNKNOWN ·Phase: PHASE2

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135 ·Status: COMPLETED ·Phase: PHASE3

ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

NCT00010153 ·Status: TERMINATED ·Phase: PHASE3

ICI 182780 in Treating Women With Metastatic Breast Cancer

NCT00012025 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

NCT00234403 ·Status: COMPLETED ·Phase: PHASE2

Faslodex Registry: Fulvestrant in Current Clinical Practice

NCT00735215 ·Status: COMPLETED

Fulvestrant in Metastatic Breast Cancer

NCT03591549 ·Status: UNKNOWN ·Phase: PHASE4

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

NCT01625286 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

NCT01320111 ·Status: COMPLETED ·Phase: PHASE2

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00138125 ·Status: TERMINATED ·Phase: PHASE2

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120 ·Status: COMPLETED ·Phase: PHASE2

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

NCT03949634 ·Status: UNKNOWN ·Phase: PHASE3

Study of AFP464 +/- Faslodex in ER + Breast Cancer

NCT01233947 ·Status: TERMINATED ·Phase: PHASE2

Zoladex® 10.8 BC RWS

NCT05184257 ·Status: COMPLETED

SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

NCT00272740 ·Status: COMPLETED ·Phase: PHASE2

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT03633331 ·Status: COMPLETED ·Phase: PHASE2

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05438810 ·Status: UNKNOWN ·Phase: PHASE3

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

NCT02626507 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses

NCT01540110 ·Status: COMPLETED ·Phase: PHASE2

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

NCT06503380 ·Status: RECRUITING

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

NCT00310089 ·Status: COMPLETED ·Phase: NA

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

NCT00752986 ·Status: TERMINATED ·Phase: PHASE2

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

NCT03447132 ·Status: COMPLETED ·Phase: PHASE3